Evidence map›Paper›PMID 41704035›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs.

Sauyeun Shin, Mehdi Liauzun, Jacobo Solorzano, Morgane Le Bras, Christine Jean, Benjamin Fourneaux, Margaux Dore, Lea Fevrier, Ismahane Belhabib, Alexia Brunel and 16 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sauyeun ShinCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Mehdi LiauzunCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Jacobo SolorzanoCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Morgane Le BrasCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-8682-2990
Christine JeanCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-6936-289X
Benjamin FourneauxInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, ICM, Université De Montpellier, Montpellier, France.
Margaux DoreCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Lea FevrierCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Ismahane BelhabibCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Alexia BrunelCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Cindy NeuzilletMedical Oncology Department Curie Institute, Versailles Saint-Quentin University, Saint-Cloud, France.
Marion LarroqueInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, ICM, Université De Montpellier, Montpellier, France.
Carine JoffreCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Stephane RocchiCentre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Cote d'Azur, Nice, France.
Nicolas FraunhofferCentre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France.
Aurelie PerraudDepartment of Digestive Surgery, Faculty of Medicine, University Hospital of Limoges and INSERM U1308 - CAPTuR, University of Limoges, Limoges, France.
Muriel MathonnetDepartment of Digestive Surgery, Faculty of Medicine, University Hospital of Limoges and INSERM U1308 - CAPTuR, University of Limoges, Limoges, France.
Vera PancaldiCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Laetitia LinaresInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, ICM, Université De Montpellier, Montpellier, France.
Juan IovannaCentre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France.
Nelson DusettiCentre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France.
Ola LarssonDepartment of Oncology-Pathology Karolinska Institutet, Stockholm, Sweden.
Remy NicolleCentre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, Université Paris Cité, Paris, France.
Stephane PyronnetCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Corinne BousquetCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.
Yvan MartineauCancer Research Center of Toulouse (CRCT), INSERM U1037, ERL5294 CNRS, University of Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-0575-4085

Funding

ARC Foundation Pancreas2024_to_CBARC Foundation Pancreas2025_to_YMChair of Bioinformatics in Oncology of the CRCT INSERM/FTCS/Pierre_Fabre_to_VPFrench National Research Agency ANR_SubRnaAct_to_YMInstitut National du Cancer 2021-073_to_YMInstitut National du Cancer INCa_2023-050_to_CBITMO Cancer of Aviesan 2021-2030_Framework_to_CJLigue Nationale Contre le Cancer EL2021_to_CBSwedish Cancer Society 222186_to_OLSwedish Research Council 2020-01665_to_OLWallenberg Academy Fellow program to OL
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) transcriptomic profiling has identified prognostic subtypes, yet patient-specific first-line therapies remain elusive. Here, we stratified PDA tumors by mRNA translation rates, a frequently dysregulated step in gene expression, using translatome profiling of 27 patient-derived xenografts (PDXs). Unsupervised analysis revealed a distinct tumor subset with low global protein synthesis but sustained translation of Integrated Stress Response (ISR) mRNAs, including ATF4. These ISR-activated cancer cells exhibited broad chemoresistance and apoptosis resistance, yet were auxotrophic for serine due to loss of PHGDH and CBS expression, impairing serine and cysteine biosynthesis. This vulnerability correlated with improved overall survival in patients with low expression of both enzymes. Notably, cancer-associated fibroblasts (CAFs) reprogrammed by ISR-activated cells, shifting from myCAF to iCAF phenotype with reduced collagen synthesis and glycine-to-serine conversion, produced serine and sustained tumor growth in amino acid-depleted environments. Our findings demonstrate the power of translatome profiling to reveal stable, drug-resistant PDA cell states and identify a targetable CAF-tumor metabolic symbiosis, opening new avenues for therapeutic intervention in this highly lethal malignancy.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalIntegrated Stress ResponsePancreatic NeoplasmsSerineAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMiceSerinecancer‐associated fibroblastintegrated stress responsemRNA translationpancreatic cancerserine metabolism

Identifiers

PMID41704035
PMCPMC13042921

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.